We examined the contribution of dermatoscopy to the reliability of the diagnosis and management of non-melanocytic skin tumours using store-and-forward teledermatology. A total of 150 patients with non-melanocytic skin tumours were enrolled into the study. The reliability of the diagnoses and management plans was measured by comparing teledermatology with face-to-face examination; the effect of adding dermatoscopy images was also analysed. The accuracy of the diagnoses was measured by comparing teledermatology with histology; the effect of adding dermatoscopy images was also analysed. Diagnostic reliability (kappa) for teledermatology without dermatoscopy was 0.75 and 0.77 for two different dermatologists, A and B. The reliability increased significantly when dermatoscopy was added, to 0.86 and 0.88 respectively (P < 0.05). The reliability of management plans without dermatoscopy was 0.67 and 0.70, but it did not increase significantly when dermatoscopy was added. The accuracy of the diagnoses was significantly increased by the addition of dermatoscopic images, from 85% to 94% for dermatologist A and from 88% to 95% for dermatologist B. Teledermatology is a reliable technique for the diagnosis and management of non-melanocytic skin tumours and the addition of dermatoscopic images increases the reliability and the accuracy of teledermatology.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/1357633X12474961 | DOI Listing |
J Clin Med
October 2024
Department of Cranio-Maxillofacial Surgery, Medical College, Jagiellonian University, 30-688 Cracow, Poland.
: Malignant eyelid tumours present a considerable challenge in the field of ophthalmic oncology, necessitating a combination of precision oncological care and meticulous reconstruction to ensure the preservation of eyelid functionality and the maintenance of facial aesthetics. : This study presents a review of the outcomes of 167 patients who underwent eyelid reconstruction following the excision of primary non-melanocytic malignant tumours. The choice of reconstruction technique was dependent on a number of factors, including the stage of the tumour, its location, and the characteristics of the patient.
View Article and Find Full Text PDFBioengineering (Basel)
October 2024
Department of Ophthalmology, University Hospital of Udine, p.le S. Maria della Misericordia 15, 33100 Udine, Italy.
Targeted drug delivery has emerged as a transformative approach in the treatment of periorbital skin malignancies, offering the potential for enhanced efficacy and reduced side effects compared to traditional therapies. This review provides a comprehensive overview of targeted therapies in the context of periorbital malignancies, including basal cell carcinoma, squamous cell carcinoma, sebaceous gland carcinoma, and Merkel cell carcinoma. It explores the mechanisms of action for various targeted therapies, such as monoclonal antibodies, small molecule inhibitors, and immunotherapies, and their applications in treating these malignancies.
View Article and Find Full Text PDFExp Dermatol
October 2024
Department of Pathology, São Paulo State University-UNESP, Botucatu, São Paulo, Brazil.
Vitamin D activates the vitamin D receptor (VDR), which dimerizes preferentially with the retinoid X receptor-α (RXRα). This heterodimer connects with genetic elements responsive to vitamin D, inhibiting or stimulating gene activity. We performed Nanostring® analysis of VDR/RXRα to compare the mRNA expression of this heterodimer and their correlated transcriptomes in non-melanoma skin cancer (basal cell carcinomas (BCC) and squamous cell carcinomas (SCC)) and melanocytic lesions (intradermal nevi (IN), and melanomas (MM)) with control skin.
View Article and Find Full Text PDFJ Dermatol
July 2024
Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
Histopathology
January 2025
Department of Anatomic Pathology, Cleveland Clinic, Cleveland, OH, USA.
Aims: Melanomas are recognised for their remarkable morphological plasticity. Some tumours may lose conventional features and/or acquire non-melanocytic characteristics, referred to as undifferentiated, dedifferentiated and transdifferentiated melanoma. Despite this phenotypical variability, melanomas typically maintain their cancer driver aberrations, affecting genes such as BRAF, NRAS and NF1.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!